Newsbenzinga
Hims & Hers Health: Investments Necessary For Long-Term Incremental Growth, Says Bullish Analyst
· Published
Article summary
HIMS stock edges lower after mixed Q2 results. Needham analyst maintains Buy rating, raises PT to $42. Company's revenue up 38.2% YoY.
An excerpt from the original article.
Comments —
Loading comments…